A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors
Open Access
- 14 November 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11), e112647
- https://doi.org/10.1371/journal.pone.0112647
Abstract
Oral treatment with asunaprevir and daclatasvir has been reported to yield a SVR ratio of 80% in patients with genotype 1b HCV infection, however, treatment failure has been reported, especially in patients with HCV strains showing the NS5A-Y93H mutation at baseline. An assay system to detect such strains was established to facilitate selection of appropriate candidates for this antiviral therapy. Primer sets and 2 types of cycling probe mixtures were designed, and real-time PCR was performed with HCV-RNA purified from 332 patients with genotype 1b HCV infection, and the results were compared with those obtained by direct sequencing. Both the wild-type and mutant strains were quantified, with a threshold of 4.0 Log copies/mL, in 295 of the 332 patients (88.9%), and the percentage of the mutant strains relative to the total HCV-RNA level in the serum was calculated. The percentage was 0% in 237 patients (80.3%) and 100% in 23 patients (7.8%), identical to the results of direct sequencing. Both wild-type and mutant strains were detected in the remaining 35 patients (11.9%), at levels between 1% and 99%, despite the mutant strains having been undetectable by direct sequencing in 11 patients with percentages of these strains of less than 25%. A novel assay system to quantify the percent RNA of Y93H mutant strains relative to the total HCV-RNA level was established. This system may be useful to determine the indication for treatment with NA5A inhibitors in patients with HCV.Keywords
This publication has 22 references indexed in Scilit:
- Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelinesThe Esophagus, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Efficacy and safety of telaprevir, a new protease inhibitor, for difficult‐to‐treat patients with genotype 1 chronic hepatitis CJournal of Viral Hepatitis, 2011
- Telaprevir for Previously Treated Chronic HCV InfectionNew England Journal of Medicine, 2010
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Epidemiology of hepatocellular carcinoma in JapanThe Esophagus, 2009
- Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow respondersHepatology, 2007
- Report of the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan†Hepatology Research, 2007
- Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus RibavirinGastroenterology, 2006